Hypercholesterolemia
Conditions
Interventions
investigational material(s)
Generic name etc : Mevalotin (Pravastatin Sodium)
INN of investigational material :
Therapeutic category code : 218 Agents for hyperlipidemias
Dosage and Administration fo
Sponsors
DAIICHI SANKYO COMPANY, LIMITED
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Hypercholesterolemia, under a Mevalotin treatment, outpatient, consenting patient, 2-years follow-up available, men aging >= 20, women aging >= 55 or after menopause, defined as a high risk group on primary prevention by JAS guideline 2007.
Exclusion criteria
Exclusion criteria: A history of cardiovascular diseases (myocardial infarction, unstable angina, stroke (excluding TIA), CABG/PCI, arteriosclerosis obliterans) before registration. A diagnosis severe arrhythmia, familial hypercholesterolemia, uncontrolled hypertension or diabetes mellitus, severe liver or renal disease, current diagnosis of severe disease (ex. malignancy), contraindicated to pravastatin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Development of cardiovascular events (myocardial infarction, unstable angina required hospitalization, CABG/PCI, stroke (excluding TIA), arteriosclerosis obliterans, and sudden and unexpected death related cardiovascular disease. | — |
Outcome results
None listed